Providence Capital Advisors LLC Has $5.24 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Providence Capital Advisors LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.5% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 22,091 shares of the medical research company’s stock after acquiring an additional 324 shares during the period. Providence Capital Advisors LLC’s holdings in IQVIA were worth $5,235,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. First Foundation Advisors raised its stake in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 43 shares during the period. Invera Wealth Advisors LLC raised its stake in shares of IQVIA by 0.3% during the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after purchasing an additional 46 shares during the period. Private Trust Co. NA raised its stake in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after purchasing an additional 48 shares during the period. Finally, Continuum Advisory LLC raised its stake in shares of IQVIA by 3.3% during the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. TD Cowen decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Barclays decreased their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Up 0.1 %

Shares of NYSE:IQV opened at $201.44 on Thursday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a market capitalization of $36.56 billion, a P/E ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. The stock has a 50 day moving average price of $220.36 and a 200-day moving average price of $226.57.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.